DOR/TDF/3TC Switch With M184V/I in People With Controlled HIV (Drive Off-Road)

Inclusion Criteria: * Adult living with HIV * Receiving stable antiretroviral treatment for at least 3 months * HIV RNA VL\<50cp/mL for at least 6 months * Presence of the M184V/I mutation in at least one previous genotype performed on plasma HIV RNA but absent from the genotype on current standard pro-viral DNA (Sanger technique) * Signed informed consent Exclusion Criteria: * History of genotypic mutation associated with resistance to DOR or TDF according to the ANRS version 32 algorithm, i.e. : * For DOR : V106A/M; Y188L; G190E/S; M230L; L100I + K103N; K103N + Y181C; K103N + P225H; F227C; At least 3 amongst: A98G, L100I, K101E, V106I, E138K, Y181C/V, G190A or H221Y * For TDF : At least 3 mutations among: M41L, E44D, D67N, T69D/N/S, L74V/I, L210W, T215A/C/D/E/G/H/I/L/N/S/V/Y/F; K65R/E/N ; Insertion at codon 69; K70E * Contraindications to the use of DOR/TDF/3TC * Hypersensitivity to doravirine, tenofovir, lamivudine or any of the excipients (lactose in particular) * Current or recent treatment with a strong CYP3A4 inducer * Breast-feeding * Patients already on DOR * Pregnant or breast-feeding women * Patients under guardianship or trusteeship